IPO Funding Public listing in 2020 with plans to raise up to around $12M signals openness to strategic deals. This creates an opening for business development outreach on co-development, licensing SBP-101, and manufacturing or clinical trial services to accelerate the pipeline.

Leadership Dynamics Recent leadership change with a new CEO in mid-2020 while the founder remains Executive Chairman, in combination with a very small team, suggests a strong appetite for external partnerships in clinical development, regulatory support, and manufacturing to scale operations.

Pancreatic Focus SBP-101 targets metastatic pancreatic ductal adenocarcinoma in a first-line setting with gemcitabine and nab-paclitaxel. This points to opportunities for oncology-focused trial supply, CRO services, formulation development, and potential licensing or co-development discussions.

Tech and Compliance A technology stack centered on Power Platform, SAP Quality Management, ServiceNow PPM and collaboration tools indicates a need for integrated quality, trial-management, data analytics, and regulatory-compliant software solutions; opportunities exist for IT modernization and vendor partnerships.

Partnership Readiness Revenue scale ($1–$10M) with modest outside funding and Florida presence suggests strong suitability for outsourcing to CDMOs/CMOs, QC labs, and logistics/providers to support clinical development and eventual commercialization.